This article was first published in Life Sciences Intellectual Property Review, November 2018.
While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed.
Greg Bacon comments in the Life Sciences Intellectual Property Review.
View the full article via subscription on the LSIPR website.